|July 24, 2014|
|07:18 EDT||ILMN||Illumina price target raised to $195 from $180 at Leerink|
Leerink raised its price target for Illumina shares to $195 citing continued instrument momentum following the company's Q2 results. The firm keeps an Outperform rating on the stock.
News For ILMN From The Last 14 Days
|July 1, 2015|
|09:35 EDT||ILMN||Illumina price target raised to $300 from $264 at Cowen|
Subscribe for More Information
|June 25, 2015|
|09:27 EDT||ILMN||Leerink life science tools analyst holds an analyst/industry conference call|
Life Science Tools and Diagnostics Dan Leonard, along with Dr. Paul Robson and Dr. Peter Kuhn, discuss the demand for Fluidigm's single cell prep products, including the impact to Biomark and the utility of CyTOF on an Analyst/Industry conference call to be held on July 1 at 2 pm.
|09:21 EDT||ILMN||BioMed Realty leases build-to-suit laboratory in Cambridge to Illumina |
BioMed Realty (BMR) announced that Illumina ILMN) has signed a 20-year lease for a 155,000 square foot new and innovative scientific research building in Cambridge, England. BioMed Realty acquired the land for the project from The Welding Institute under a long term ground lease, enlarging BioMed Realty's Granta Park campus in Cambridge, England.
|June 17, 2015|
|07:51 EDT||ILMN||NIH draft FY16 funding budget better than expected at BofA/Merrill|
Last night, the House Appropriations Labor/Health and Human Services Subcommittee released its draft FY16 funding budget. The bill proposed a FY16 funding increase of 3% for the National Institute of Health, versus BofA/Merrill's forecast for a 1% increase. The firm said the proposed boost in funding would be a positive for the Life Sciences & Tools sector, especially iIllumina (ILMN) and Thermo Fisher (TMO) which have the most exposure.